Publication:
Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature

dc.contributor.authorChuda Rujitharanawongen_US
dc.contributor.authorLeena Chularojanamontrien_US
dc.contributor.authorSuphattra Trakanwittayaraken_US
dc.contributor.authorSumruay Pinkaewen_US
dc.contributor.authorSasipha Nuttawongen_US
dc.contributor.otherFaculty of Medicine Siriraj Hospital, Mahidol Universityen_US
dc.date.accessioned2022-08-04T11:13:13Z
dc.date.available2022-08-04T11:13:13Z
dc.date.issued2021-01-01en_US
dc.description.abstractLivedoid vasculopathy (LV) is an uncommon, chronic, and recurrent thrombo-occlusive vascular disorder. Data specific to LV in Thai population remains scarce. This study aimed to evaluate the clinical course and treatment outcomes of LV in Thai patients, and to perform a literature review for studies that reported on anticoagulant treatment in LV. Seventy-four patients with a mean age of 37.6 ± 14.7 years were included. The female to male ratio was 5.2:1, and the median follow-up was 10.5 months. Most patients had primary LV disorder. Forty-eight patients were improved with treatments, with a median duration of 11.4 months. Combination treatments were commonly used, including anti-inflammatories, antiplatelets, and immunosuppressants. Add-on therapy with anticoagulant or psoralen plus ultraviolet-A (PUVA) led to disease improvement in a majority of the patients treated. Kaplan-Meier analysis demonstrated that 38.5%, 53.7%, and 57.9% would have disease improvement at 1, 2, and 3 years, respectively. Of 39 studies (n = 219) that reported on anticoagulant treatment in LV, anticoagulant drug was used as monotherapy in 104 patients. The mean duration of anticoagulant treatment was 7.2 ± 3.8 months, which led to disease improvement in 97 patients (93.3%). Bleeding side effect was found in 9 patients (8.7%). The highest incidence of LV was found among females aged 30 to 40 years. Combination therapy with anti-inflammatory drugs, antiplatelet drugs, and immunosuppressants led to disease improvement. The observed efficacy of add-on PUVA or anticoagulant is promising and should be further investigated. Further studies are needed to guide the development of an LV management guideline.en_US
dc.identifier.citationDermatologic Therapy. Vol.34, No.1 (2021)en_US
dc.identifier.doi10.1111/dth.14569en_US
dc.identifier.issn15298019en_US
dc.identifier.issn13960296en_US
dc.identifier.other2-s2.0-85096849659en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/78879
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096849659&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleLivedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literatureen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096849659&origin=inwarden_US

Files

Collections